Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms
Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms
NCT ID: NCT06974058 Phase: NA Status: COMPLETED Enrollment: 15 Completion: 2025-12-14
Conditions
Long COVID
Interventions
Nasafytol® (Quercetin/Curcumin Supplement)
Summary
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.
Primary Outcome
Change in Overall Symptom Burden